A systematic review and meta-analysis of data from randomized controlled trials ( RCTs ) to evaluate the efficacy and safety of Certolizumab pegol ( Cimzia ) was performed.
A total of five RCTs, involving 1,891 participants, were included. The meta-analysis revealed that Certolizumab significantly increased the overall ( induction + maintenance therapy ) response ( odds ratio, OR=1.565, 95% CI 1.056-2.321, P = 0.026 ) and remission rates ( OR=1.626, 95% CI 1.297-2.038, P less than 0.001 ) compared with placebo.
Certolizumab significantly increased the response and remission rates when given as maintenance therapy ( OR=2.171, 95% CI 1.644-2.866, P less than 0.001 and OR=1.888, 95% CI 1.390-2.565, P less than 0.001 ), but not as induction therapy ( OR=1.234, 95% CI 0.912-1.671, P = 0.173 and OR=1.361, 95% CI 0.974-1.901, P = 0.071 ).
Certolizumab ( induction + maintenance therapy ) did not significantly increase the treatment-related toxicity rate compared with placebo ( OR=0.985, 95% CI 0.799-1.214, P = 0.887 ).
In conclusion, Certolizumab may be an efficacious treatment for Crohn's disease as maintenance therapy and appears to have a favorable safety profile. ( Xagena )
Da W et al, Adv Ther 2013;30:541-553